CAS |
864070-44-0 |
Chinese Name |
恩格列净 |
English Name |
Empagliflozin |
Synonym |
BI 10773 |
Purity |
HPLC≥98% |
Unit |
Bottle |
Molecular Formula |
C23H27ClO7 |
Molecular Weight |
450.91 |
Appearance |
White to off-white solid |
Storage |
Powder : -20℃, 2 years;In solvent(mother liquid): -20℃, 1 month; -80℃, 6 months |
Solubility |
Soluble in DMSO≥5mg/ml |
MDL |
MFCD22566222 |
EC |
EINECS 620-176-8 |
InChIKey |
OBWASQILIWPZMG-QZMOQZSNSA-N |
InChI |
InChI=1S/C23H27ClO7/c24-18-6-3-14(23-22(28)21(27)20(26)19(11-25)31-23)10-15(18)9-13-1-4-16(5-2-13)30-17-7-8-29-12-17/h1-6,10,17,19-23,25-28H,7-9,11-12H2/t17-,19+,20+,21-,22+,23-/m0/s1 |
PubChem CID |
11949646 |
SMILES |
ClC(C=CC([C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)=C2)=C2CC(C=C3)=CC=C3O[C@H]4CCOC4 |
Description |
Empagliflozin is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor. |
Target Point |
SGLT |
Passage |
Membrane Transporter&Ion Channel |
Data Literature Source |
[1]. Grempler R, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab. 2012 Jan;14(1):83-90.
[2]. Cheng ST, et al. The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes. PLoS One. 2016 Jan 25;11(1):e0147391.
[3]. Nikole J.ByrneBSc, et al. Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure. JACC Basic Transl Sci. 2017 Aug;2(4):347-354.
[4]. Sakaeda T, et al. Susceptibility to serious skin and subcutaneous tissue disorders and skin tissue distribution of sodium-dependent glucose co-transporter type 2 (SGLT2) inhibitors. Int J Med Sci. 2018 Jun 13;15(9):937-943. |
Specification |
10mM*1mL in DMSO 50mg 100mg 250mg |